Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 10, Number 3, June 2017, pages 159-165

The Trend of Tranexamic Use in Upper Gastrointestinal Bleeding Ulcers

**Table 1.** Gender and Age Division, Mean Value for Systolic Blood Pressure, Hemoglobin and Pulse Together With Cardinal Symptoms and Abdominal Pain in Total and for Each Group
	Total (N = 101)	TXA (N = 57)	No TXA (N = 44)	P value
Women, N (%)	45 (44.6)	24 (42.1)	21 (47.7)	0.857
Men, N (%)	56 (55.4)	33 (59.9)	23 (52.3)	0.866
Mean age, years	71 CI (69 - 75)	73	69	0.514
Mean systolic blood pressure	121 CI (115 - 127)	119	123	0.237
Hemoglobin, mean value	98 CI (92 - 103)	93	102	0.177
Pulse, mean value	87 CI (84 - 92)	84	90	0.211
Hematemesis, N (%)	50 (49.5)	32 (60.4)	18 (41.9)	0.386
Melena, N (%)	75 (74.3)	42 (79.2)	33 (76.7)	1.000
Hematochezia, N (%)	11 (12.1)	7 (14.3)	4 (9.5)	0.755
Abdominal pain or discomfort, N (%)	40 (43.0)	19 (38.0)	21 (48.8)	0.355

Table 1. Gender and Age Division, Mean Value for Systolic Blood Pressure, Hemoglobin and Pulse Together With Cardinal Symptoms and Abdominal Pain in Total and for Each Group

Total (N = 101)

TXA (N = 57)

No TXA (N = 44)

P value

Women, N (%)

45 (44.6)

24 (42.1)

21 (47.7)

0.857

Men, N (%)

56 (55.4)

33 (59.9)

23 (52.3)

0.866

Mean age, years

71 CI (69 - 75)

0.514

Mean systolic blood pressure

121 CI (115 - 127)

119

123

0.237

Hemoglobin, mean value

98 CI (92 - 103)

102

0.177

Pulse, mean value

87 CI (84 - 92)

0.211

Hematemesis, N (%)

50 (49.5)

32 (60.4)

18 (41.9)

0.386

Melena, N (%)

75 (74.3)

42 (79.2)

33 (76.7)

1.000

Hematochezia, N (%)

11 (12.1)

7 (14.3)

4 (9.5)

0.755

Abdominal pain or discomfort, N (%)

40 (43.0)

19 (38.0)

21 (48.8)

0.355

**Table 2.** Medical History in Each Group Including Cardiovascular Disease and Median Value for Number of Used Risk Medication
	TXA	No TXA	P value
Cardiovascular disease, N (%)	40 (70.2)	28 (63.6)	0.487
Number of medications comprising a risk for ulcer disease Median value (min. - max.)	1 (0 - 4)	1 (0 - 3)	0.732

Table 2. Medical History in Each Group Including Cardiovascular Disease and Median Value for Number of Used Risk Medication

TXA

No TXA

P value

Cardiovascular disease, N (%)

40 (70.2)

28 (63.6)

0.487

Number of medications comprising a risk for ulcer disease Median value (min. - max.)

1 (0 - 4)

1 (0 - 3)

0.732

**Table 3.** Treatment and EGD Within 24 h for Each Group Separately
	TXA	No TXA	P value
x: no statistics because PPI was a constant.
PPI, N (%)	57 (100)	44 (100)	x
Adrenaline, N (%)	20 (36.4)	8 (18.6)	0.053
Other treatments, N (%)	16 (28.1)	5 (11.9)	0.052
H. pylori eradication, N (%)	26 (46.4)	27 (61.4)	0.137
EGD < 24 h	47 (82.5)	31 (70.5)	0.154

Table 3. Treatment and EGD Within 24 h for Each Group Separately

TXA

No TXA

P value

x: no statistics because PPI was a constant.

PPI, N (%)

57 (100)

44 (100)

Adrenaline, N (%)

20 (36.4)

8 (18.6)

0.053

Other treatments, N (%)

16 (28.1)

5 (11.9)

0.052

H. pylori eradication, N (%)

26 (46.4)

27 (61.4)

0.137

EGD < 24 h

47 (82.5)

31 (70.5)

0.154

**Table 4.** Outcome Factors for Each Group Including MAF, Re-Bleeding, Days at Hospital and Treatment at the Surgery Department and/or ICU
	> 0 MAF	Re-bleeding, N (%)	Days at hospital, median value (min. - max.)	Treatment at Surgery Department, N (%)	Treatment at Surgery Department and ICU, N (%)
TXA	43 (84.3)	10 (17.5)	5 (1 - 15)	43 (75.4)	14 (24.6)
No TXA	20 (64.5)	6 (13.6)	3 (0 - 39)	41 (93.2)	3 (6.8)
P-value	0.039	0.594	0.005	0.018	0.018

Table 4. Outcome Factors for Each Group Including MAF, Re-Bleeding, Days at Hospital and Treatment at the Surgery Department and/or ICU

> 0 MAF

Re-bleeding, N (%)

Days at hospital, median value (min. - max.)

Treatment at Surgery Department, N (%)

Treatment at Surgery Department and ICU, N (%)

TXA

43 (84.3)

10 (17.5)

5 (1 - 15)

43 (75.4)

14 (24.6)

No TXA

20 (64.5)

6 (13.6)

3 (0 - 39)

41 (93.2)

3 (6.8)

P-value

0.039

0.594

0.005

0.018

**Table 5.** Gender and Median Age for Outcome
	MAF	Re-bleeding	Treatment at the Surgery Department	Treatment at the Surgery Department and ICU
Men, N (%)	37 (66.1)	10 (17.9)	46 (82.1)	10 (17.9)
Women, N (%)	26 (57.8)	6 (13.3)	38 (84.4)	7 (15.6)
Age, median value (min. - max.)	76 (38 - 94)	74 (24 - 90)	73 (24 - 94)	75 (49 - 90)

Table 5. Gender and Median Age for Outcome

MAF

Re-bleeding

Treatment at the Surgery Department

Treatment at the Surgery Department and ICU

Men, N (%)

37 (66.1)

10 (17.9)

46 (82.1)

10 (17.9)

Women, N (%)

26 (57.8)

6 (13.3)

38 (84.4)

7 (15.6)

Age, median value (min. - max.)

76 (38 - 94)

74 (24 - 90)

73 (24 - 94)

75 (49 - 90)